Bet_Noire BofA has lowered its rating of Hims & Hers ( NYSE: HIMS ) to underperform from buy, citing Amazon’s ( AMZN ) push into the hair loss and erectile dysfunction treatment markets. “Today HIMS generates 80%+ gross margins from its core hair loss/ED markets and the substantial.
Back to Health Page
